Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Lifestyle Drug Drama Heats up

November 28, 2005 | A version of this story appeared in Volume 83, Issue 48

Medicis, the dermatology products firm that reached an agreement to purchase Inamed earlier this year, is now itself the subject of a $2.2 billion acquisition bid from breast implant maker Mentor. Medicis has rebuffed Mentor's offer and issued a deadline to Inamed, which is the subject of a competing bid by Botox-maker Allergan. Medicis gave Inamed until Dec. 6 to recommend that its shareholders reject the Allergan offer or risk paying a $90 million termination fee under its agreement with Medicis. Meanwhile, Mentor has indicated it is willing to improve its offer for Medicis by infusing cash. All players are vying for a leadership position in the so-called lifestyle therapies market, which is estimated to be worth $25 billion annually today and projected to grow exponentially over the next decade.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.